يعرض 1 - 10 نتائج من 13 نتيجة بحث عن '"Rojo, Ricardo"', وقت الاستعلام: 1.56s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel

    المؤلفون: Rojo, Ricardo, Calvo Alén, Jaime, Prada, Álvaro, Valor, Santiago, Roy, Garbiñe, López-Hoyos, Marcos, Cervera, Ricard, Sánchez Mateos, Paloma, Jurado Roger, Aurora

    المصدر: In Autoimmunity Reviews December 2023 22(12)

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Corrigendum to “Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus – A proposal from an expert panel” [Autoimmunity Reviews, Volume 22, Issue 12, December 2023, 103479]

    المؤلفون: Rojo, Ricardo, Calvo Alén, Jaime, Prada, Álvaro, Valor, Santiago, Roy, Garbiñe, López-Hoyos, Marcos, Cervera, Ricard, Mateos, Paloma Sánchez, Roger, Aurora Jurado

    المصدر: In Autoimmunity Reviews February 2024 23(2)

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.

    المؤلفون: Blauvelt, Andrew, Silverberg, Jonathan I., Lynde, Charles W., Bieber, Thomas, Eisman, Samantha, Zdybski, Jacek, Gubelin, Walter, Simpson, Eric L., Valenzuela, Fernando, Criado, Paulo Ricardo, Lebwohl, Mark G., Feeney, Claire, Khan, Tahira, Biswas, Pinaki, DiBonaventura, Marco, Valdez, Hernan, Cameron, Michael C., Rojo, Ricardo

    المصدر: Journal of the American Academy of Dermatology; Jan2022, Vol. 86 Issue 1, p104-112, 9p

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.

    المؤلفون: Burgos-Vargas, Ruben, Cardiel, Mario, Xibillé, Daniel, Pacheco-Tena, César, Pascual-Ramos, Virginia, Abud-Mendoza, Carlos, Mahgoub, Ehab, Rahman, Mahboob, Fan, Haiyun, Rojo, Ricardo, García, Erika, Santana, Karina

    المصدر: Reumatología Clínica; Jan2019, Vol. 15 Issue 1, p43-53, 11p

    مصطلحات موضوعية: GOLIMUMAB, BLOOD sedimentation, RHEUMATOID arthritis, KINASE inhibitors, MEDICAL care surveys, RHEUMATOLOGY

    مصطلحات جغرافية: MEXICO

    View record from ScienceDirect Full Text Finder
    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.

    Alternate Title: Tofacitinib, un inhibidor oral de la quinasa Janus, para el tratamiento de artritis reumatoide en pacientes de Latinoamérica: eficacia y seguridad de estudios fase 3 y de extensión a largo plazo. (Spanish)

    المؤلفون: Radominski, Sebastião Cezar, Cardiel, Mario Humberto, Citera, Gustavo, Goecke, Annelise, Jaller, Juan Jose, Vannucci Lomonte, Andrea Barranjard, Miranda, Pedro, Velez, Patricia, Xibillé, Daniel, Kwok, Kenneth, Rojo, Ricardo, García, Erika Gabriela

    المصدر: Reumatología Clínica; jul-ago2017, Vol. 13 Issue 4, p201-209, 9p

    مصطلحات موضوعية: JANUS kinases, PROTEIN-tyrosine kinases, AUTOIMMUNE diseases, RHEUMATISM, NILOTINIB

    View record from ScienceDirect Full Text Finder
    أضف إلى المفضلة
  6. 6
    دورية أكاديمية
    27582 Abrocitinib improves work productivity through improvement in pruritus and sleep: Results from the JADE MONO-2 study in patients with moderate-to-severe atopic dermatitis (AD).

    المؤلفون: Yosipovitch, Gil, Deleuran, Mette, Su, John, Fonacier, Luz, Bushmakin, Andrew G., Cappelleri, Joseph C., Feeney, Claire, Thorpe, Andrew, Rojo, Ricardo, Valdez, Hernan, Myers, Daniela E.

    المصدر: Journal of the American Academy of Dermatology; 2021 Supplement, Vol. 85 Issue 3, pAB153-AB153, 1p

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  7. 7
    دورية أكاديمية
    27603 Rapid itch relief with abrocitinib predicts later skin clearance: A post hoc analysis vs dupilumab and placebo in JADE COMPARE.

    المؤلفون: Ständer, Sonja, Yosipovitch, Gil, Simpson, Eric L., Kwatra, Shawn G., Thyssen, Jacob P., Valdez, Hernan, Rojo, Ricardo, DiBonaventura, Marco, Zhang, Fan, Cameron, Michael, Feeney, Claire

    المصدر: Journal of the American Academy of Dermatology; 2021 Supplement, Vol. 85 Issue 3, pAB155-AB155, 1p

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  8. 8
    دورية أكاديمية
    27523 Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis (AD) from the phase 2 and phase 3 clinical trial program.

    المؤلفون: Simpson, Eric L., Silverberg, Jonathan I., Nosbaum, Audrey, Winthrop, Kevin, Guttman-Yassky, Emma, Hoffmeister, Karin M., Zhang, Min, Farooqui, Saleem A., Johnson, Susan, Thorpe, Andrew, Rojo, Ricardo

    المصدر: Journal of the American Academy of Dermatology; 2021 Supplement, Vol. 85 Issue 3, pAB150-AB150, 1p

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  9. 9
    دورية أكاديمية
    27237 Effect of abrocitinib vs dupilumab and placebo on patient-reported outcomes (PROs) in moderate-to-severe atopic dermatitis (AD) in JADE COMPARE.

    المؤلفون: Yosipovitch, Gil, Thyssen, Jacob P., Paul, Carle, Kwatra, Shawn G., Chu, Chia-Yu, Rojo, Ricardo, Valdez, Hernan, Feeney, Claire, Zhang, Fan, Myers, Daniela E., DiBonaventura, Marco

    المصدر: Journal of the American Academy of Dermatology; 2021 Supplement, Vol. 85 Issue 3, pAB133-AB133, 1p

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  10. 10
    دورية أكاديمية
    Patient-Reported Outcomes (PROs) With Abrocitinib Treatment in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (AD): Results From the Phase 3 JADE TEEN Study.

    المؤلفون: McMichael, Amy, Cork, Michael, Teng, Joyce, Rojo, Ricardo, Valdez, Hernan, Zhang, Fan, Myers, Daniela, Chan, Gary, DiBonaventura, Marco

    المصدر: Journal of Allergy & Clinical Immunology; 2021 Supplement, Vol. 147 Issue 2, pAB156-AB156, 1p

    View record from ScienceDirect Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء